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Introduction
Gorham-Stout disease (GSD) is a rare, locally destructive musculoskeletal disorder of unknown etiology. GSD
affecting the skull base is a particularly challenging disease
entity. Skull-base GSD has a high propensity for causing
life-threatening complications such as cerebrospinal ﬂuid
(CSF) leaks, meningitis, and osteomyelitis. Additionally,
skull-base GSD is often surgically unresectable. Although
the primary treatment modality for GSD is surgery, prior
series demonstrate that GSD is radiosensitive, and radiation therapy (RT) is indicated for refractory or symptomatic cases not amenable to surgery. Older case series have
described the management of skull-base GSD with 2dimensional or 3-dimensional RT techniques. Recent
technological advances, such as intensity modulated RT
(IMRT) and image guided RT, have allowed for the delivery of highly conformal RT, potentially improving disease
outcomes and minimizing toxicity for head and neck
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cancer. Here we describe a case of GSD of the skull base
successfully treated with conformal IMRT, and a provide
a review of the pertinent literature.

Patient Case
Presentation
A 27-year-old previously healthy woman initially presented in May 2017 with several months of progressive
tooth loss and a 5-day history of progressive left mandibular swelling, trismus, and decreased oral intake after
minor trauma to her face. Maxillofacial computed tomography (CT) without contrast revealed a nondisplaced fracture of the left mandibular angle with hypoplastic
appearance of the left mandibular body and ramus with
superimposed areas of permeative destruction and erosion (Fig 1A). She then underwent left mandibulectomy,
reconstruction of left mandibular defect with left ﬁbular
fascio-osseous free-ﬂap, and placement of mandibular
plate in June 2017. Final pathology revealed chronic
inﬂammation, marrow ﬁbrosis, and vascular malformation consistent with GSD. Her postoperative course was
uncomplicated.
She was seen for routine follow-up in January 2018, at
which time she began to have pain in her left jaw region
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Fig 1 Axial diagnostic computed tomographic images of the maxillofacial bones without contrast reveal osseous changes indicative of
Gorham-Stout disease (blue arrows) including osteolysis and bone resorption. May 2017 scan demonstrating changes in left mandible
(A). January 2018 scan demonstrating progressive mandibular disease crossing midline to the right (B). February 2020 scan demonstrating further disease progression with new osteolysis within the maxilla (C-D), left sphenoid, lateral orbital wall, zygomatic arch, and
squamosal temporal bone (E-F).

and was noted to have progressive, near complete tooth
loss in the mandibular region. Maxillofacial CT without
contrast medium demonstrated progressive bone resorption of her left mandible extending into her right mandible (Fig 1B). She received 1 dose of intravenous
bisphosphonate therapy (zoledronic acid, 5 mg) in April
2018 and was recommended to take calcium 1200 mg
daily and vitamin D 50,000 IU per week. She then underwent total mandibulectomy and reconstruction with a
total mandibular prosthesis with right radial forearm freeﬂap in August 2018. Final pathology demonstrated atrophic-appearing bone with focal vascular malformation,
consistent with GSD. Her postoperative course was again
uncomplicated.
She was seen in routine follow-up in February 2020, at
which time she felt a knot in her left cheek region. Maxillofacial CT without contrast demonstrated interval osteolysis involving the left sphenoid, lateral orbit, zygomatic
arch, and squamosal temporal bones, consistent with
GSD (Fig 1C-F). She was evaluated by a multidisciplinary
team including otolaryngology, radiation oncology, and
neurosurgery, and the patient elected to proceed with
conventionally fractionated IMRT.

Treatment planning and delivery
The patient received a CT simulation without intravenous contrast lying supine with a custom thermoplastic
immobilization mask with head neutral and arm on arm.
CT images were transferred to the RT planning system.

Diagnostic CT from February 2020 was fused to the primary image data set to assist with target delineation. The
treating radiation oncologist contoured a clinical target volume (CTV) with multidisciplinary input from the patient’s
otolaryngologist and neuroradiologist (Fig 2 A-D), as
reported in a previous study.1 The CTV was designed to
encompass all areas of GSD. Planning target volume (PTV)
was created using a margin of 3 mm from the CTV. PTV
was trimmed from skin to 3 mm to limit skin dose. Organs
at risk were delineated including the optic nerves, optic chiasm, brain stem, lacrimal glands, middle ears, corneas,
esophagus, eyes, larynx, lens, lips, pharyngeal constrictors,
spinal cord, and submandibular glands.
An IMRT treatment plan was developed to deliver
4200 cGy in 21 once daily fractions (Fig 3A-F and Fig 4).
The dose was within the recommended range of 3600 to
4500 cGy based on the German Society of Radiation
Oncology (DEGRO) guidelines.2 Institutional dose constraints were used during planning as follows: spinal cord
maximum dose <40 Gy, spinal cord +5 mm maximum
dose <45 Gy, optic nerve maximum dose <54 Gy, optic
chiasm maximum dose <54 Gy, brain stem maximum
dose <54 Gy, lacrimal gland mean dose <26 Gy, middle
ear mean dose <35 Gy, eye maximum dose <45 Gy, larynx mean dose <25 Gy, parotid gland mean dose <20 Gy,
submandibular gland mean dose <25 Gy, lips mean dose
<20 Gy, esophagus mean dose <20 Gy, and pharyngeal
constrictors mean dose <50 Gy. Maximum dose within
PTV was <120% prescription (Rx) dose, and minimum
dose within PTV was ≥95% Rx dose. PTV coverage goal
was V95% Rx dose ≥95%.

Fig 2 Axial (A-C) and coronal (D) computed tomographic images of the head and skull base from simulation radiation therapy planning study demonstrating clinical target volume in green and planning target volume in cyan.
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Fig 3

Gorham-Stout skull-base radiation therapy
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Axial (A-C), coronal (D-E), and sagittal (F) views of the intensity modulated radiation therapy plan for the patient.

All treatments were performed using the Ethos system
(Varian Medical Systems Inc). The patient received a daily
cone beam CT before RT delivery to assist with set-up.
During treatment the patient experienced expected side
effects as per Common Terminology Criteria for Adverse
Events version 5.0, including grade 2 oral mucositis (managed with oral narcotic pain medications), grade 1 dysphagia, grade 1 xerostomia, grade 1 skin erythema
(managed with over-the-counter skin creams), and grade
1 xerophthalmia (managed with over-the-counter eye
lubricants). The patient did not require any treatment
breaks. After completion of RT, the patient has had an
excellent clinical course without evidence of disease progression or signiﬁcant late morbidity. She does have mild
grade 2 lymphedema in the left facial region, attributed to
a combination of surgical disruption of facial lymphatics
and RT. Maxillofacial CT without contrast performed
approximately 3, 9, and 12 months post-RT demonstrated
stability of osteolysis (Fig 5A-F).

Discussion and Literature Review
GSD, or “vanishing bone disease,” is a rare, locally
destructive musculoskeletal disorder of unknown etiology.
The ﬁrst case was described in 1838.3 In 1955, Gorham
and Stout summarized the clinical and histopathologic
features in 2 cases.4 GSD typically affects younger adults
(<40 years old) and does not have any predilection for
race, gender, or familial history.5,6 GSD can affect any
anatomic region but is more commonly found in the

Fig 4

skull, ribs, shoulders, and pelvis.4,5,7,8 The symptoms are
nonspeciﬁc and based on the musculoskeletal site affected.
Symptoms can include pain or muscle weakness, and
patients often present with pathological fracture.5,9,10
GSD is a diagnosis of exclusion, and workup is required
to rule out infectious, neoplastic, or osseous disease processes. Although there are a combination of radiologic
and histologic features that support the diagnosis of
GSD,4,11,12 the precise pathophysiological mechanism is
not well understood.6 Furthermore, the clinical course is
unpredictable, as both spontaneous regression and rapid
progression have been reported.5,9
There is no standard treatment approach for GSD. The
2 primary forms of treatment are surgery and RT.7 Medical therapy with osteoclast inhibiting drugs such as
bisphosphonates or interferon (alfa-2b) therapy has also
been reported, although these are typically used in conjunction with surgery or RT. Surgical options include
resection of effected bone with reconstruction or amputation.7 The DEGRO guidelines suggest RT is an effective
therapy with local control of »80% and minimal
toxicity.2,7,13 The prognosis for GSD is generally good,
though patients with GSD affecting areas such as the skull
base and spine can have increased morbidity and mortality given the proximity to critical structures.14
To the best of our knowledge, this is the ﬁrst case of
skull-base GSD treated with conformal IMRT reported in
the literature. Skull-base GSD is particularly challenging
and can be life-threatening secondary to CSF leaks, resulting in recurrent meningitis, medullary compression, or
cervical instability.15,16 In addition, skull-base GSD has a

Dose volume histogram of the intensity modulated radiation therapy plan for the patient.
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Fig 5 Follow-up axial diagnostic computed tomograms of the maxillofacial bones without contrast at 3 months (A-C) and 9 months
(D-F) post completion of radiation therapy demonstrate stabilization of disease without new areas of osteolysis.

high propensity for causing local symptoms, as seen with
our case, that signiﬁcantly affect patient quality of life.
Therefore, optimal management of skull-base GSD is crucial. Surgery can be considered for up-front management
but can result in signiﬁcant morbidity, including graft
resorption, recurrent CSF leaks, and infections.15-17 In
patients with particularly advanced disease, surgery may
be technically challenging due to the lack of bone substance for ﬁxation of autologous or alloplastic materials.
Our patient’s GSD was refractory to 2 surgical procedures
and medical therapy, with RT used as a salvage therapy
option.
Descriptions of RT for GSD have historically been for
cases of progressive GSD resistant to surgical intervention, as with our patient. RT has also demonstrated efﬁcacy as deﬁnitive ﬁrst-line therapy. RT for skull-base GSD
has mostly been reported in single case reports (Table 1)
using 2-dimensional or 3-dimensional RT techniques,
with a total RT dose ranging from 20 to 45 Gy. A majority
of patients (10 of 13) described in the literature demonstrated no local progression after RT. Although data are
limited, there is a suggestion of dose-dependency with
regard to control of GSD, with in-ﬁeld progression occurring in 2 cases after total doses of 36 Gy and 35 Gy, and
out-of-ﬁeld progression in 1 case after 36 Gy, whereas no
patients who received >36 Gy had disease progression.

These data inform the DEGRO guideline recommendations (36 to 45 Gy).2
Our case highlights the safety and early efﬁcacy of conformal IMRT for the treatment of skull-base GSD refractory to surgery and medical management. Our patient
was treated with a total dose of 42 Gy, consistent with the
DEGRO guidelines. Our patient tolerated her RT course
well with minimal acute toxicity. In-ﬁeld progression has
been reported as late as 46 months post-RT.7 Although
long-term disease control and late toxicity cannot be fully
assessed without longer follow-up, the patient is currently
12 months post-RT without evidence of disease progression or signiﬁcant late morbidity. IMRT has demonstrated signiﬁcant beneﬁt in decreasing toxicity from RT
for head and neck cancer.18-20 Our patient is young, and
further disease progression or development of treatmentrelated toxicity could have devastating consequences. Furthermore, radiation-induced sarcoma after management
of skull-base GSD has been reported, placing importance
on reducing the total treatment volume.21 Proton therapy
has emerged as another modality to deliver RT for skull
base tumors while minimizing integral dose to organs at
risk.22,23 Therefore, we recommend that conformal RT
techniques (IMRT or proton therapy) be considered for
the treatment of skull-base GSD refractory to surgical and
medical management.

Advances in Radiation Oncology: January−February 2022
Table 1

Gorham-Stout skull-base radiation therapy
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Summary of published studies of radiation therapy for management of skull base Gorham-Stout disease

Authors
Kurczynski and Horwitz (1981)22

Site(s)
SB

Dose
(cGy)
2000

Dose per
fraction (cGy)
200

Follow-up
(mo)
24

Results
No progression, +BR

Heffez et al (1983)12
Dunbar et al (1993)13

SB
SB
SB, CS
SB
SB
SB, CS
SB, CS
SB, CS
SB, CS
SB, CS
SB, CS
SB, CS

4500
4500
4400
4000
2340
4000
4140
3500
3600
3600
4000
3060

180
180
200
200
180
200
180
175
200
200
200
180

12
65
118
77
12
24
3
12
24
46
54
111

No progression, +BR
No progression/remodeling
No progression/remodeling
No progression
Stabilization and sclerosis
No progression, +BR
No progression, +BR
In-ﬁeld progression
Out-of-ﬁeld progression
In-ﬁeld progression
No progression
No progression

Schiel and Prein (1993)23
Frankel et al (1997)24
Khosrovi et al (1997)25
Mawk et al (1997)
Girn et al (2006)
Heyd et al (2011)7

Abbreviations: BR = bone remineralization; CS = cervical spine; SB = skull base.
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